Law Offices of Thomas J. Lamb

  • Asbestos & Mesothelioma
  • Benzene Diseases
  • Camp Lejeune Cases
  • Drug Injury
  • Free Case Evaluation
  • About Us

Contrast Agents And Gadolinium Deposition Disease: Medical Literature Review, September 2018 – February 2019

March 25, 2019 By Law Offices of Thomas J. Lamb, P.A.

We continue to monitor the medical literature for developments related to gadolinium retention in connection with our investigation of cases of Gadolinium Deposition Disease (GDD) in patients who received injections of gadolinium based contrast agents for their MRI, MRA, or CT scan procedure. Presented below is a collection of medical articles … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gadolinium, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents

May 2018 Gadolinium Deposition Disease Update Issued By Health Canada

July 23, 2018 By Law Offices of Thomas J. Lamb, P.A.

In May 2018 Health Canada announced the results of its second safety review of Magnevist, MultiHance, Omniscan, and Optimark, as well as other gadolinium contrast injections for MRIs, CT scans, and other radiology procedures. In May 2018 Health Canada issued this document, “Summary Safety Review – Gadolinium based contrast agents – Assessing the … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gad, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents, gadolinium-containing contrast

Gadolinium Retention Higher For Linear Agents Than Macrocyclic Agents

June 15, 2018 By Law Offices of Thomas J. Lamb, P.A.

Gadolinium Based Contrast Agents (GBCAs) are substances that are injected into patients during a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images. However, as explained below, unfortunately some patients have experienced gadolinium side effects after these contrast agents were … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents

MRI Contrast Agents: Gadolinium Retention Warnings Added To Drug Label

May 21, 2018 By Law Offices of Thomas J. Lamb, P.A.

The gadolinium contrast agents safety warnings announced by the FDA in December 2017 started to be seen on new drug labels approved in the spring of 2018. It is important to understand that symptoms of gadolinium-related medical conditions can first appear anywhere from just a few hours until several weeks after the MRI or MRA procedure when a … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gad, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents, gadolinium-containing contrast

Gadolinium Deposition Disease Explained: How It Is Diagnosed, And More

May 16, 2018 By Law Offices of Thomas J. Lamb, P.A.

A person who received an injection of a gadolinium-based contrast agent (GBCA) may develop some medical conditions following their MRI or MRA procedure which could be symptoms of gadolinium deposition disease. These various gadolinium-related symptoms include: Persistent headache; “Brain fog”; Skin that appears spongy or rubbery, … [Read more...]

Filed Under: Unsafe Drugs Tagged With: gadolinium, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents, gadolinium-containing contrast

Gadolinium-Based Contrast Agents: Timeline of FDA Regulatory Actions

February 28, 2018 By Law Offices of Thomas J. Lamb, P.A.

In my last article on Gadolinium based contrast agents (GBCAs), I discussed some of the side effects of these injections, which are administered to patients during a Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA). While GBCAs have started to draw attention in the pharmaceutical products liability legal realm, they have … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Ablavar, Dotarem, Eovist, Gadavist, gadolinium, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents, GBCAs, Magnevist, mra contrast agents side effects, mri contrast agents side effects, MultiHance, Nephrogenic systemic fibrosis, NSF, Omniscan, OptiMARK, ProHance

Gadolinium Deposition Disease can Result from use of Contrast Agents During MRI & MRA Procedures

February 23, 2018 By Law Offices of Thomas J. Lamb, P.A.

What are Gadolinium-Based Contrast Agents (GBCAs)? GBCAs are substances that are injected into patients during Magnetic Resonance Imaging (MRI) or Magnetic Resonance Angiography (MRA) in order to produce clearer radiology images. Here is a list of GBCAs that are currently approved by the FDA: Ablavar Dotarem Eovist Gadavist … [Read more...]

Filed Under: Unsafe Drugs Tagged With: Ablavar, Dotarem, Eovist, Gadavist, gadolinium, Gadolinium deposition disease, gadolinium retention, Gadolinium storage condition, gadolinium-based contrast agents, GBCAs, Magnevist, mra contrast agents side effects, mri contrast agents side effects, MultiHance, Nephrogenic systemic fibrosis, NSF, Omniscan, OptiMARK, ProHance

Find What You Want Here

Get Free Case Evaluation

We encourage you to submit an online Case Evaluation Form – it is confidential and there is no obligation.

Or call our toll-free number, 800-426-9535, to speak directly to attorney Tom Lamb about your possible case.

Feel Free To Contact Us

Quick Contact Form
 
Send an Email to Tom Lamb

(800) 426-9535

Main Navigation Menu

  • About Our Firm
  • Asbestos-Mesothelioma Cases
  • Benzene Disease Claims
  • PFAS Firefighter Gear Lawsuits
  • Camp Lejeune Cases
  • GenX Water Cancer Cases
  • Drug Injury Lawsuits
  • Breast Implant Cancer Cases
  • Philips Breathing Devices Cases
  • Case Evaluation Menu
  • Quick Contact Form
  • Frequently Asked Questions
  • Medical Records Charges
  • Collection of Articles
  • Sitemap

Lamb Law Office Newsletter

Lamb Law Office Newsletter provides periodic updates about some of the cases that we are working on for clients, as well as an information resource you might find helpful.

Subscribe using Form below.

Subscription Form

* indicates required

Our Other Websites

Drug Injury Law
Drug Injury Watch
Drug Safety Developments
Asbestos & Mesothelioma

Contact Information

Law Offices of Thomas J. Lamb, P.A.
1908 Eastwood Road, Suite 225
Wilmington, North Carolina 28403
910-256-2971 | 800-426-9535
TJL@LambLawOffice.com

  • Home
  • Frequently Asked Questions
  • Disclaimer and Copyright Notices

Copyright © 2023 · Law Offices of Thomas J. Lamb, P.A.